Merck KGaA to acquire Bio-Techne for $11.3bn
Merck, the Darmstadt-based science and technology giant, has entered into a definitive agreement to acquire Minneapolis-based Bio-Techne Corporation. This all-cash transaction represents an enterprise value of approximately $11.3bn. The purchase price provides a 36% premium over Bio-Techne’s one-month volume-weighted average trading price, reflecting a substantial premium. From an operational standpoint, this acquisition accelerates Merck’s positioning in high-growth, next-generation life sciences…